Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High KPNA2 signals poor outcomes for RCC

Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

Publish date:: November 8, 2018

Key clinical point: High KPNA2 expression is associated with increased risk of death in clear cell and papillary renal cell carcinoma (RCC).

Major finding: Survival was poorer for patients with clear cell RCC having high KPNA2 protein levels (74 vs. 171 months) or mRNA levels (hazard ratio for death, 1.45) and for patients with papillary RCC having high KPNA2 mRNA levels (HR, 6.2).

Study details: A retrospective dual cohort study of 240 clinic patients and 771 Cancer Genome Atlas patients.

Disclosures: The authors reported that they had no conflict of interests.

Read the article here.

Citation:

Kristiansen G et al. Clin Genitourin Cancer. 2018 Oct 22. doi: 10.1016/j.clgc.2018.10.008

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,